To determine whether IL2-REH-MSA could prevent the activation of non-tumor-specific CD8+ T cells, we compared IL12-MSA binding by SIY-nonreactive CD8+ T cells from mice treated with either IL2-MSA or IL2-REH-MSA. The gene discussed is TPO; the disease is neoplasm.